EU/3/12/1049

About

On 10 October 2012, orphan designation (EU/3/12/1049) was granted by the European Commission to Clovis Oncology UK Limited, United Kingdom, for rucaparib for the treatment of ovarian cancer.

Rucaparib has been authorised in the EU as Rubraca since 24 May 2018.

Key facts

Active substance
Rucaparib
Medicine name
Rubraca
Disease / condition
Treatment of ovarian cancer
Date of decision
10/10/2012
Outcome
Positive
Orphan decision number
EU/3/12/1049

Review of designation

The Committee for Orphan Medicinal Products reviewed the orphan designation of Rubraca at the time of marketing authorisation, and confirmed that the orphan designation should be maintained.

More information is available in the PDF iconorphan medicine assessment report .

Sponsor's contact details

Clovis Oncology UK Limited
Sheraton House
Castle Park
Cambridge
CB3 0AX
United Kingdom
Telephone: +44 1223 370037
E-mail: info@clovisoncology.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating